Sugi Predict

Sugi Predict / Compounds / SCHEMBL7175205

SCHEMBL7175205

SCHEMBL7175205

Cc1cccc(C)c1C(=O)Pc1ccc(OC(C)(C)C)cc1.[LiH]

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 3/20 0.33
▸ PPARA Q07869 6/20 0.33
▸ PPARG P37231 3/20 0.33
▸ CCR5 P51681 1/20 0.31
▸ MEN1 O00255 2/20 0.31
▸ KMT2A Q03164 2/20 0.31
▸ CYP1A2 P05177 2/20 0.31
▸ CYP3A4 P08684 2/20 0.31
▸ CYP2C19 P33261 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ LCK P06239 1/20 0.31
▸ ABCB11 O95342 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ HTR2A P28223 1/20 0.31
▸ PMP22 Q01453 1/20 0.31
▸ CYP2C9 P11712 1/20 0.30
▸ PPARD Q03181 1/20 0.30
▸ L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182840 0.91 TYK2 (0.36) PPARAPPARGMEN1KMT2ACYP1A2
SCHEMBL7175586 0.87 KDM4E (0.33) ACACBPPARAPPARGMEN1KMT2A
SCHEMBL7175886 0.86 EPHX2 (0.33) ACACBPPARAPPARGMAPTL3MBTL1
SCHEMBL7182384 0.85 POLB (0.38) ACACBPPARAPPARGMEN1KMT2A
SCHEMBL7189515 0.83 ATM (0.42) CCR5MEN1KMT2AKDM4ETSHR
SCHEMBL7175906 0.83 CA12 (0.42) MEN1KMT2AMAPT
SCHEMBL7182777 0.82 ATM (0.32) CCR5
SCHEMBL7187567 0.82 MAPK8 (0.35) ACACBPPARAPPARGMEN1KMT2A
SCHEMBL7186838 0.82 ACACB (0.31) ACACBPPARAPPARG
SCHEMBL7180835 0.81 MEN1 (0.43) PPARAMEN1KMT2ACYP2D6L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ACACB 914/4885PPARA 3039/4885PPARG 2956/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ACACB 555/4885PPARA 2624/4885PPARG 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.